Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment

The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies. Dr Lunning is an associate professor in the Division of Oncology & Hematology, associate vice chair of research in the Department of Internal Medicine, and assistant vice chancellor of clinical research at the University of Nebraska Medical Center in Omaha.

In this episode, Dr Lunning sat down with Danielle M. Brander, MD, to discuss the evolution of chronic lymphocytic leukemia (CLL) management. Dr Brander is an assistant professor of medicine, hematologic malignancies, and cellular therapy, as well as a member of the Duke Cancer Institute in Durham, North Carolina.

Drs Lunning and Brander highlighted how the timing of a CLL diagnosis affects patients’ eligibility for early treatment intervention; optimal risk-assessment tools for newly diagnosed CLL; patient characteristics and disease factors that influence the choice of frontline CLL therapy; and more.